GSK343: Practical EZH2 Inhibition Workflows
2026-09-16
GSK343 provides a cell-permeable, SAM-competitive route to test EZH2-dependent H3K27me3 regulation in cancer models. This guide connects target-engagement assays, proliferation studies, and immune-related epigenetic questions while emphasizing solvent control, orthogonal validation, and the limits of extrapolating in vitro findings.
Ranolazine Workflows for Cardiac Ischemia Research
2026-09-16
Build reproducible Ranolazine assays that connect late sodium current modulation with glucose-centered metabolic readouts. This guide provides practical dosing, ischemia-model workflows, liver-cell applications, and assay controls while clearly separating established evidence from exploratory cross-domain interpretation.
Citrate Molarity Shapes mRNA-LNP Function
2026-09-15
Binici and colleagues show that citrate buffer molarity can alter cellular uptake and expression from mRNA-LNPs even when conventional size, polydispersity, and encapsulation measurements appear similar. The study positions aqueous-phase formulation as an important process variable and cautions that standard critical quality attributes may not fully predict biological performance.
Bradykinin: Practical Vascular Assay Workflows
2026-09-15
Bradykinin (BA5201) provides a defined peptide reagent for studying endothelium-dependent vasodilation, vascular permeability modulation, smooth muscle contraction, pain mechanisms, and inflammation-related responses. It is intended for controlled scientific research only, not for diagnostic, therapeutic, or medical use, and prepared solutions should be used promptly rather than stored long term.
Arachidonic Acid Accelerates Vaccine Humoral Immunity
2026-09-14
The reference study identifies dietary arachidonic acid as a potential adjuvant strategy for accelerating rabies vaccine-induced neutralizing antibodies. Mouse protection studies, human volunteer data, and mechanistic analyses connect arachidonic acid metabolism in lymph nodes with PGI2–cAMP–PKA signaling, CD86 expression, and AID activation in B cells.
Oseltamivir acid: Influenza Neuraminidase Workflows
2026-09-14
Build reproducible influenza neuraminidase, cell-based antiviral, resistance, and oncology assays with a defined active metabolite rather than relying on prodrug conversion. This guide combines practical formulation, controls, translational model selection, and troubleshooting for research-only use.
Angiotensin 1/2 (5-7): A Translational RAS Lens
2026-09-13
A thought-leadership perspective on Angiotensin 1/2 (5-7), connecting its defined H2N-Ile-His-Pro-OH sequence to renin-angiotensin system research, hypertension models, assay strategy, and emerging SARS-CoV-2 receptor-binding evidence.
From Lactylation to Viability: A ccRCC Translational Playboo
2026-09-12
The AARS2–ULK1 lactylation axis reframes clear cell renal cell carcinoma as a metabolic and autophagy-dependent disease. This thought-leadership guide explains how Cell Counting Kit-8 (CCK-8) Plus can connect mechanistic perturbation to scalable viability, proliferation, cytotoxicity, and drug-response decisions while keeping redox-related interpretation rigorously controlled.
Machine Learning Discovery of Senolytic Compounds
2026-09-11
The reference study shows that cost-effective machine learning trained only on published screening data can prioritize senolytic candidates from chemical libraries. Experimental validation identified ginkgetin, periplocin, and oleandrin in human cell models, demonstrating a practical route for reducing early-stage screening costs while retaining biological selectivity as the key test.
v-Agatoxin-IVA and N-Type Calcium Channel Blockade
2026-09-11
Sidach and Mintz showed that v-Agatoxin-IVA remains a selective high-affinity P-type calcium-channel blocker, yet at micromolar exposure it can also weakly modulate N-type and Q-like currents. Their whole-cell recordings in rat subthalamic and sympathetic neurons demonstrate why toxin concentration, membrane potential, and neuronal context are essential when assigning calcium-channel subtype identity.
p-Cresyl sulfate: Assay Workflows for CKD Research
2026-09-10
Build reproducible p-Cresyl sulfate experiments that separate protein binding, endothelial repair, proliferation, and apoptosis effects. The workflow connects chronic kidney disease models with biliary epithelial injury, cardiovascular risk, and uremic toxin clearance research while emphasizing fresh-solution handling and matched controls.
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-09-10
The reference study develops chemically modified CDKN1A/p21 mRNA in lipid nanoparticles for localized intravesical treatment of bladder cancer. Its data support tumor suppressor replacement as a nonviral strategy that restores nuclear p21, inhibits tumor-cell growth, and suppresses orthotopic tumors while limiting systemic exposure.
Epacadostat: From IDO1 Potency to Immune Readouts
2026-09-09
Epacadostat (INCB024360) connects biochemical IDO1 inhibition with cellular and whole-blood immune phenotypes. This guide presents a decision framework for interpreting target engagement, cytokine responses, and translational immuno-oncology data.
SB 202190: p38 MAP Kinase Inhibitor Workflow
2026-09-09
Build a controlled p38 perturbation workflow with SB 202190 for inflammation research, cancer therapeutics research, and apoptosis assay development. A complementary colorectal cancer organoid–T-cell study shows how this inhibitor can be added as a mechanistic test of tumor-driven immune differentiation, while careful controls distinguish pathway effects from general cytotoxicity.
ABT-888 (Veliparib): PARP1/2 Research Guide
2026-09-08
ABT-888, also called Veliparib, is a selective PARP1 and PARP2 inhibitor used to study DNA repair inhibition and combination cancer therapy. Preclinical data support its evaluation as a chemotherapy and radiation sensitizer, while model-specific response and formulation limits remain important.